Theravance Biopharma, Inc. (FRA:0TB)

Germany · Delayed Price · Currency is EUR

16.30

+0.20 (1.24%)

Last updated: Feb 20, 2026, 8:04 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Discovery (Research), Development and Commercialization of Human Therapeutics	64.38M	57.42M	51.35M	55.31M	71.86M
Discovery (Research), Development and Commercialization of Human Therapeutics Growth	12.12%	11.84%	-7.17%	-23.03%	-2.12%
Total	64.38M	57.42M	51.35M	55.31M	71.86M
Total Growth	12.12%	11.84%	-7.17%	-23.03%	-2.12%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	64.38M	57.20M	51.12M	55.27M	70.32M
United States Growth	12.55%	11.89%	-7.51%	-21.40%	28.41%
Europe	-	223.00K	222.00K	38.00K	1.54M
Europe Growth	-	0.45%	484.21%	-97.53%	-91.76%
Total	64.38M	57.42M	51.35M	55.31M	71.86M
Total Growth	12.12%	11.84%	-7.17%	-23.03%	-2.12%

Source: S&P Global Market Intelligence.